Abstract:Background Low muscle strength and mass with possible impaired physical performance characterizes the muscle disease known as sarcopenia. When not diagnosed or treated, the risk of falls, fractures, hospitalization, hospital costs, longer hospital stays, and negative outcomes increases. In the presence of comorbidities, such as cardiovascular diseases, sarcopenia can be significant and serious. In these patients, muscle weakness has attracted considerable attention in recent years since it is deemed an independent risk factor for disability and a strong predictor of premature death. The SARC-F (simple questionnaire to rapidly diagnose sarcopenia), a valid and consistent instrument to detect people at risk of adverse outcomes associated with sarcopenia, including functional decline, can be used as a screening tool. It consists of 5 items self-reported by patients based on their perceptions regarding strength limitations, the ability to walk, rise from a chair, climb stairs and a number of falls. Objectives Analyze the risk of sarcopenia and identify associated factors in hospitalized older adults with cardiovascular disease. Methods This is a cross-sectional study conducted with 23 hospitalized older adults with cardiovascular disease in a tertiary hospital of the Federal District, Brazil, classified into two groups: with or without risk of sarcopenia according to the SARC-F. Demographic (age and sex), clinical (number of medications and body mass index –BMI) and physical data (muscle strength and mass) were collected. Muscle strength was assessed using handgrip dynamometry and the Medical Research Council (MRC) scale, and mass by means of electrical bioimpedance. These data were compared between the groups using the student´s t and Mann-Whitney U tests. Results There was a risk of sarcopenia in 39.1% (n=9) of the sample. In comparison analyses, the group of older adults at risk of sarcopenia were older (mean difference: 14.39 years [95%CI 8.23 – 20.55]; p=0.001), exhibited lower handgrip strength (mean difference: 9.36 KgF [95%CI 0.874 – 17.854]; p=0.032), more frequent muscle weakness on the MRC scale (X²(1)=5.367, p=0.047) and lower appendicular muscle mass (mean difference: 0.763 [95%CI 0.113 – 1.414]; p=0.024). The groups showed no differences for sex, BMI and number of continuous use drugs (p>0.05). Conclusion This study found that older adults at risk of sarcopenia are older and obtain worse physical results when compared to their risk-free counterparts. The SARC-F was able to identify hospitalized patients with lower strength and muscle mass. Implications The findings show the need to identify hospitalized older adults at risk of sarcopenia using a simple, fast, low-cost, noninvasive assessment, which may contribute to the establishment of early identification strategies in a hospital setting, aimed at developing more assertive measures.

THERE IS NO CORRELATION BETWEEN STAGES OF NAFLD ASSESSED BY LIVER BIOPSY AND THE DIAGNOSTIC CRITERIA FOR SARCOPENIA IN ACTIVE POPULATIONS: A CROSS-SECTIONAL STUDY

Sarcopenia is Associated with the Presence of Nonalcoholic Fatty Liver Disease in Zhejiang Province, China: a Cross-Sectional Observational Study

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis

A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study

P-8 OSTEOSARCOPENIA AND FIBROSIS SEVERITY IN NON-ALCOHOLIC FATTY LIVER DISEASE

Prevalence of Sarcopenia and Its Defining Components in Non-alcoholic Fatty Liver Disease Varies According to the Method of Assessment and Adjustment: Findings from the UK Biobank

Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis

Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: An observational study with ISarcoPRM algorithm

Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice

Agreement and diagnostic differences among three definitions of sarcopenia in patients with chronic hepatitis C

Relationship of the Degree of Sarcopenia with the Severity of Nonalcoholic Fatty Liver Disease and Cardiometabolic Risk in Adolescents

Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease

Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis

Comparative analysis of Sarcopenia in hospitalized elderly: exploring the impact of liver cirrhosis

What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?

Sarcopenic Obesity in Chronic Kidney Disease: Challenges in Diagnosis Using Different Diagnostic Criteria

RISK OF SARCOPENIA AND ASSOCIATED FACTORS IN HOSPITALIZED OLDER ADULTS WITH CARDIOVASCULAR DISEASE

RELATIONSHIP BETWEEN SARCOPENIA AND OSTEOPOROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE.

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease

Prevalence and impact of sarcopenia in individuals with heart failure with reduced ejection fraction (the SARC-HF study): A prospective observational study protocol